The next step from high-flux dialysis: Application of sorbent technology

James F. Winchester, Claudio Ronco, James A. Brady, Larry D Cowgill, Jamie Salsberg, Eric Yousha, Mike Choquette, Robert Albright, Jonathan Clemmer, Vadim Davankov, Maria Tsyurupa, Ludmila Pavlova, Mikhail Pavlov, Gerald Cohen, Walter Hörl, Frank Gotch, Nathan W. Levin

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


The current foci of renal replacement therapy with dialysis are middle molecular weight toxins, consisting of small proteins, polypeptides and products of glycosylation and lipoxygenation. Conventional high-flux dialysis is not efficient at removing these molecules, explaining the increased interest in using sorbents to supplement dialysis techniques. Prototype biocompatible sorbents have been developed and investigated for middle molecule removal; these have been shown, in man, to remove β2-microglobulin, angiogenin, leptin, cytokines and other molecules, without reducing platelets and leukocytes. Extensive clinical studies are underway to demonstrate the clinical utility and safety of adding routinely a sorbent hemoperfusion device to hemodialysis.

Original languageEnglish (US)
Pages (from-to)81-86
Number of pages6
JournalBlood Purification
Issue number1
StatePublished - 2002


  • β2-Microglobulin
  • Adsorption
  • Angiogenin
  • Biocompatibility
  • Cytokines
  • Hemoperfusion
  • Leptin
  • Sorbents

ASJC Scopus subject areas

  • Nephrology
  • Hematology


Dive into the research topics of 'The next step from high-flux dialysis: Application of sorbent technology'. Together they form a unique fingerprint.

Cite this